Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention

Drugs and Aging

Volumn 12, Issue 5, 1998, Pages 377-390

  Szekanecz, Zoltan ^a,b   Koch, Alisa E ^a,c   Kunkel, Steven L ^d   Strieter, Robert M ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; CYTOKINE RECEPTOR; GROWTH FACTOR; MONOCLONAL ANTIBODY;

ANGIOGENESIS; CELL INFILTRATION; GENE TRANSFER; HUMAN; IMMUNOMODULATION; LEUKOCYTE; OSTEOPENIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS;

EID: 0031920031     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812050-00004     Document Type: Review

References (167)

1. Harris Jr ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 332: 1277-87
2. Koch AE, Kunkel SL, Strieter RM. Cytokines in rheumatoid arthritis. J Invest Med 1995; 43: 28-38
3. Brennan FM, Field M, Chu CQ, et al. Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991; 30: 76-80
4. Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347-53
5. Firestein GS. The immunopathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1991; 3: 398-406
6. Lipsky PE, Davis LS, Cush JJ, et al. The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 1989; 11: 123-62
7. Szekancez Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. J Invest Med 1496; 44: 124-35
8. Szekanecz Z, Halloran MM, Haskell CJ, et al. Mediators of angiogenesis: the role of cellular adhesion molecules. Trends Glycosci Glycotechnol. In press
9. Colville-Nash PR, Scott DL. Angiogenesis in rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1492; 51: 919-25
10. Haskard DO. Cell adhesion molecules in rheumatoid arthritis. Curr Opin Rheumatol 1995; 7: 229-34
11. Canalis E. Regulation in bone remodeling. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders ot mineral metabolism. Kelseyville: American Society lor Bone and Mineral Research, 1990: 23-6
12. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling, emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-11
13. Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991; 20: 256-72
14. Tannenbaum H. Osteopenia in rheumatology practice: pathogenesis and therapy. Semin Arthritis Rheum 1984; 13: 337-48
15. Taki H, Sugiyama E, Mino T, et al. Spontaneous production of interleukin-11 and its inhibition by indomethacin and dexamethasone in freshly isolated rheumatoid synoviocytes [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129
16. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440
17. Feldman M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. In: Dixon FJ, editor. Advances in immunology. Vol. 64. London: Academic Press, 1997: 283-350
18. Barrera P, Boerbooms AMT, van de Putte LBA, et al. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996; 25: 234-53
19. Dayer J-M, Arend VVP. Cytokines and growth factors. In: Kelle WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology, 5th ed. Philadelphia: Saunders, 1997: 267-86
20. 2 production by human synovial cells. J Clin Invest 1986; 77: 645-8
21. McCachren S, Greer PK, Niedel JE. Regulation of human synovial fibroblast collagenase messenger RNA by interleukin-1. Arthritis Rheum 1989; 32: 1539-45
22. 2 levels of human synovial cells. Arthritis Rheum 1987; 30: 562-6
23. Postlethwaite AE, Raghow R, Stricklin GP, et al. Modulation of fibroblast functions by interleukin I: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol 1988; 106: 311-8
24. Goldring MB, Birkheak J, Sandell LJ, et al. Interleukin 1 suppresses expression of cartilage and specific types I and III collagens in human chondrocytes. J Clin Invest 1988; 82: 2026-37
25. Dalton BJ, Connor JR, Johnson WJ. Interleukin-1 induces interleukin-1 alpha and interleukin-1 beta gene expression in synovial fibroblasts and peripheral blood monocytes. Arthritis Rheum 1989; 32: 279-87
26. Guerne P-A, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. J Clin Invest 1989; 83: 585-92
27. Koch AE, Kunkel SL, Burrows JC, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1491; 147: 2187-95
28. Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90: 772-9
29. Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410-22
30. Abbot SK, Kaul A, Stevens CR, et al. Isolation and culture of synovial microvascular endothelial cells: characterization and assessment of adhesion molecule expression. Arthritis Rheum 1992; 35: 401-6
31. Lindsley HB, Smith DD, Davis LS, et al. Regulation of the expression of adhesion molecules by human synoviocytes. Semin Arthritis Rheum 1992; 21: 330-4
32. Bellido T, Jilka RL, Boyce BF, et al. Regulation of interleukin-6, osteoclastogenesis and hone mass by androgens: the role of the androgen receptor. J Clin Invest 1995; 95: 2886-95
33. Bismar H, Diel I, Ziegler R, et al. Increased cytokine secretion by human hone marrow cells aller menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995; 80: 3351-5
34. Horowitz MC. Cytokines and estrogen in bone. Science 1993; 260: 626-8
35. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88-91
36. Buchan G, Barrett K, Turner M, et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 1988; 73: 449-55
37. Nouri AM, Panayi GS, Goodman SM. Cytokines and the chronic inflammation of rheumatic disease: 1. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984; 55: 295-302
38. Shore A, Jaglal S, Keystone EC. Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 1986; 65: 293-302
39. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993; 21 (10): S447-63
40. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8
41. Koch AE, Kunkel SL, Harlow LA, et al. Macrophage inflammatory protein-1α: a novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994; 93: 921-8
42. Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94: 1012-8
43. Tessier P, Audette M, Cattaruzzi P, et al. Up-regulation by tumour necrosis factor-α of intercellular adhesion molecule 1 expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis-Rheum 1993; 36: 1528-39
44. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987; 329: 630-2
45. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-8
46. Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-5
47. Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125-32
48. Manicourt D-H, Triki R, Fukuda K, et al. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 490-9
49. Roubenoff R, Roubenoff RA, Ward LM, et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505-10
50. Tetta C, Camussi G, Modena V, et al. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 665-7
51. Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9: 137-9
52. Le J, Vilcrek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588-602
53. Motro B, Itin A, Sachs L, et al. Pattern of interleukin-6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A 1990; 87: 3092-6
54. Rosen EM, Liu D, Setter E, et al. Interleukin-6 stimulates motility of vascular endothelium. EXS 1991; 59: 194-205
55. Houssiau FA, Devogelaer J-P, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8
56. Helle M, Boeije L, de Groot E, et al. Sensitive ELISA for interleukin-6 detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991; 138: 47-56
57. Waage A, Kaufmann C, Espevik T, et al. Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol 1989; 50: 394-8
58. Madhok R, Crilly A, Murphy E, et al. Gold therapy lowers serum interleukin 6 levels in rheumatoid arthritis. J Rheumatol 1993; 20: 630-3
59. Tan PLJ, Farmiloe S, Yeoman S, et al. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol 1990; 17: 1608-12
60. Field M, Chu C, Feldmann M, et al. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int 1991; 11: 45-50
61. Miossec P. Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13 Suppl. 12P: S13-6
62. van Roon JA, van Roy JL, Gmelig-Meyling FH, et al. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996; 39: 829-35
63. Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995; 154: 1432-9
64. Vannier E, de Waal-Malefyt R, Salazar-Montes A, et al. Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. Blood 1996; 87: 3307-15
65. Klareskog L, Ronnelid J, Holm G. Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition. J Intern Med 1995; 238: 191-206
66. Sugiyama E, Kuroda A, Taki H, et al. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 1995; 22: 2020-6
67. Koch AE, Fong TW, Volpert OV, et al. Interleukin-4 is an inhibitor of angiogenesis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S304
68. 2+ in murine osteoclasts. J Biol Chem 1994; 269: 13817-24
69. Katsikis PD, Chu CQ, Brennan FM, et al. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517-27
70. Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304-10
71. Owens JM, Gallagher AC, Chambers TJ. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol 1996; 157: 936-40
72. Isomaki P, Luukkainen R, Toivanen P, et al. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1693-702
73. Woods JM, Haines GK, Shah MR, et al. Interleukin-13 in synovial fluid and tissue of patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129
74. Halloran MM, Hosaka S, Woods JM, et al. A new function for interleukin-13 as an endothelial chemotaxin [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129
75. McInnes IB, Al-Mughales J, Field M, et al. The role of interleukin-15 in T cell migration and activation in rheumatoid arthritis. Nature Med 1996; 2: 175-82
76. Campbell IK, Waring P, Novak U, et al. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor α. Arthritis Rheum 1993; 36: 790-4
77. Pepper MS, Ferrara N, Orci L, et al. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. J Cell Sci 1995; 108: 73-83
78. Waring PM, Carroll GJ, Kandiah DA, et al. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1993; 36: 911-5
79. Hamilton JA, Waring PM, Filonzi EL. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-α. J Immunol 1993; 150: 1496-502
80. Villiger PM, Geng Y, Lotz M. Induction of cytokine expression by leukemia inhibitory factor. J Clin Invest 1993; 91: 1575-81
81. Wisniewski HG, Maier R, Lotz M, et al. TSG-6: a TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis. J Immunol 1993; 151: 6593-601
82. Alvaro-Gracia JM, Zvaifler MNJ, Brown CB, et al. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-α. J Immunol 1991; 146: 3365-71
83. Alvaro-Garcia JM, Zvaifler NJ, Firestein GS. Granulocyte/ macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 1989; 170: 865-75
84. Leizer T, Cebon J, Layton JE, et al. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 1990; 76: 1989-96
85. Remmers EF, Sano H, Wilder RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 191-9
86. Sato N, Beitz JG, Kato J, et al. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993; 142: 1119-30
87. Lafyatis R, Remmers EF, Roberts AB, et al. Anchorage-independent growth of synoviocytes from arthritic and normal joints. J Clin Invest 1989; 83: 1267-76
88. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149-56
89. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-39
90. Sano H, Forough R, Maier JAM, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990; 110: 1417-26
91. Goddard DH, Grossman SL, Williams WV, et al. Regulation of synovial cell growth: coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum 1992; 35: 1296-303
92. Takeuchi M, Otsuka T, Matsui N, et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994; 37: 662-72
93. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994; 63: 265-311
94. Wiseman DM, Polverini PJ, Kamp DW, et al. Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity Biochem Biophys Res Commun 1988; 157: 793-800
95. Chu CQ, Field M, Abney E, et al. Transforming growth factor-β1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 1991; 86: 380-6
96. Szekanecz Z, Haines GK, Harlow LA, et al. Increased synovial expression of transforming growth factor (TGF)-β receptor endoglin and TGF-β1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995; 76: 187-94
97. Wahl SM, Allen JB, Wong HL, et al. Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium. J Immunol 1990; 145: 2514-9
98. Gunther M, Haubeck HD, van de Leur E, et al. Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes. Arthritis Rheum 1994; 37: 395-405
99. Wahl SM, Costa GL, Corcoran M, et al. Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 1993; 150: 3553-60
100. Kava RA, Olsen NJ, Postlethwaite AE, et al. Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: implications for TGH-β-driven synovial inflammation and hyperplasia. J Exp Med 1991; 173: 1121-32
101. Brandes ME, Allen JB, Ogawa Y, et al. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108-13
102. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993; 90: 1937-41
103. Koch AE, Hallorun MM, Hosaka S, et al. Hepatocyte growth factor: a cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum 1996; 39: 1566-75
104. Walz A, Kunkel SL, Strieter RM. C-X-C chemokines - an overview. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 1-25
105. Taub DD. C-C chemokines - an overview. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 27-54
106. Kunkel SL, Lukacs N, Kasama T, et al. The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996; 58: 6-12
107. Oppenheim JJ, Zachariae COC, Mukaida N, et al. Properties of the novel proinflammatory supergene 'intererine' cytokine family. Annu Rev Immunol 1991; 9: 617-48
108. Koch AE, Kunkel SL, Strieter RM. Chemokines in arthritis. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 103-16
109. Peichl P, Ceska M, Effenberger F, et al. Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Stand J Immunol 1991; 34: 333-9
110. Rampart M, Herman AG, Grillet B, et al. Development and application of a radioimmunoassay for interleukin-8: detection of interleukin-8 in synovial fluids from patients with inflammalory joint disease. Lab Invest 1992; 66: 512-8
111. Endo H, Akahoshi T, Takagishi K, et al. Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res 1991; 10 (4): 245-52
112. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-801
113. Hu DE, Hori Y, Fan T-PD. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993; 17: 135-43
114. Castor CW, Andrews PC, Swartz RD, et al. The origin, variety, distribution, and biologic fate of connective tissue activating peptide-III isoforms: characteristics in patients with rheumatic, renal, and arterial disease. Arthritis Rheum 1993; 36: 1142-53
115. Bedard PA, Golds EE. Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts. J Cell Physiol 1993; 154: 433-41
116. Koch AE, Kunkel SL, Shah MR, et al. Growth-related gene product alpha: a chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995; 155: 3660-6
117. Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992; 149: 722-7
118. Hachicha M, Rathanaswami P, Schall TJ, et al. Production of monocyte chemotactic protein-1 in human type B synoviocytes. Arthritis Rheum 1993; 36: 26-34
119. Taub DD, Conlon K, Lloyd AR, et al. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1α and MIP-1β. Science 1993; 260; 355-8
120. Akahoshi T, Wada C, Endo H, et al. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Arthritis Rheum 1993; 36: 762-71
121. Fahey III TJ, Tracey KJ, Tekamp-Olson P, et al. Macrophage inflammatory protein I modulates macrophage function. J Immunol 1991; 148: 2764-9
122. Koch AE, Kunkel SL, Shah MR, et al. Macrophage inflammatory protein-1 beta: a C-C chemokine in osteoarthritis. Clin Immunol Immunopathol 1995; 77: 307-14
123. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-71
124. Rathanaswami P, Hachicha M, Sadick M, et al. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. J Biol Chem 1993; 268: 5834-9
125. Robinson E, Keystone EC, Schall TJ, et al. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol 1995; 101: 398-407
126. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-15
127. Evans CH, Robbins PD. Pathways to gene therapy in rheumatoid arthritis. Curr Opin Rheumatol 1996; 8: 230-4
128. Nita I, Ghivizzani SC, Galea-Lauri J, et al. Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39: 820-8
129. Kingsley G, Panayi G, Lanchbury J. Immunotherapy of rheumatic diseases - practice and prospects. Immunol Today 1991; 12: 177-9
130. Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996; 8: 195-200
131. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42
132. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082-91
133. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077-81
134. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259-62
135. Kyle V, Coughlan RJ, Tighe H. Beneficial effect of monoclonal antibody to interleukin-2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 428-9
136. Harris Jr ED. Treatment of rheumatoid arthritis. In: Kelley WN, Harris Jr ED, Russy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1996: 912-23
137. American College of Rheumatology ad hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-22
138. Goodwin JS. Nonsteroidal antiinflammatory drugs. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1959-67
139. Cash JM, Hoffman GS. Glucocorticoids. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1947-58
140. Cash JM, Hoffman GS. Immunomodulatory pharmaceuticals. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1980-92
141. Thomas R, Carroll GJ. Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244-52
142. Danis VA, Franic GM, Rathjen DA, et al. Circulating cytokine levels in patients with rheumatoid arthritis: resulls ot a double blind trial with sulphasalazine. Ann Rheum Dis 1992; 51: 946-50
143. Dougudos M. Cyclosporin in rheumatoid arthritis. Clin Exp Rheumatol 1994; 12 Suppl. 11: S75-8
144. Fagrinoli S, van Thiel DH. Immunophillin hinding agents. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1993-2001
145. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40-5
146. Fauci AS, Young Jr KR. Immunomodulatory agents. In: Kelley WN, Harris Jr ED, Russy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders. 1996: 797-821
147. Girasole G, Jilka RL, Passen G, et al. 17β-Estradiol inhibits interleukin-6 production by hone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992; 89: 883-91
148. Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on hone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499-505
149. Lemire JM, Archer DC, Beck L, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995; 125 Suppl.: 1704S-8S
150. Lacey DL, Erdmann JM, Tan HL, et al. Murine osteoblast interleukin 4 receptor expression: upregulation by 1,25 dihydroxyvitamin D3. J Cell Biochem 1993; 53: 122-34
151. Pennanen N, Lapinjoki S, Urtli A, et al. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916-22
152. Choy EHS. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis. Drugs Aging 1998; 12: 139-48
153. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31
154. Williams RO, Feldmann M, Maini RN. Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784-8
155. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36: 1681-90
156. Brennan FM, Jackson A, Chantry D, et al. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 1: 244-7
157. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-fusion protein. N Engl J Med 1997; 337: 141-97
158. Drevlow BE, Lovis R, Hang R, et al. Recomhinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996; 39: 257-65
159. Seckinger P, Lowenthal JW, Williamson K, et al. A urine inhibitor of interleukin I activity that blocks ligand binding. J Immunol 1987; 139: 1546-9
160. Carler DB, Deibel Jr MR, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344: 633-8
161. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 1993; 36: 781-9
162. Krzesicki RF, Halfield CA, Bienkowski MJ, et al. Regulation of expression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts. J Immunol 1993; 150: 4008-18
163. Lebsack ME, Paul CC, Bloedow DC. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1991; 34 Suppl.: S45
164. Chole RA, Faddis BT, Tinling SP. In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist. J Bone Miner Res 1995; 10: 281-4
165. Chernajovsky Y, Annenkov A, Herman C, et al. Gene therapy for rheumatoid arthritis; theoretical considerations. Drugs Aging 1998; 12: 29-41
166. Raz E, Watanabe A, Baird SM, et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A 1993; 90: 4523-7
167. Koch AE, Kurata H, Hosaka S, et al. Use of the rat adjuvant-induced arthritis as a model for rheumatoid arthritis gene therapy [abstract]. Arthritis Rheum 1996; 39 Suppl.: S248